Abstract CT513: Phase I study of IBI322 (anti-CD47/PD-L1 bispecific antibody) monotherapy therapy in patients with advanced solid tumors in China

Authors: Jie Wang, Yuping Sun, Qian Chu, Jianchun Duan, Rui Wan, Zhijie Wang, Jun Zhao, Haoyuan Li, Yingmei Guo, Yuling Chen, Yan Wang

Published: 2022-06-15

DOI: 10.1158/1538-7445.am2022-ct513

Source: Full article